Home › Activist investors › Sarissa Capital
Campaign activist. Positions and campaigns from Sarissa Capital’s SEC filings. Updated November 21, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| Amarin Corporation PLC/UK | 6.1%25,743,900 shares | Schedule 13D/A, filed Aug 27, 2026 | Sep 5, 2023 | Decreased Aug 27, 2026 | ▼ 1.99 pts | Decreased | Standard Item 4 language |
| Ironwood Pharmaceuticals Inc | 5.8%9,444,944 shares | Schedule 13D/A, filed Mar 19, 2026 | Mar 19, 2026 | — | — | — | Standard Item 4 language |
| Innoviva, Inc. | 2.66%1,890,604 shares | 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 31, 2026 | Nov 14, 2016 | — | ▲ 0.04 pts | — | 13F: none stated |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“On March 25, 2025, Mr. Mark DiPaolo, a member of Issuer's board of directors (the "Board"), notified the Issuer that he does not intend to stand for reelection to the Board at the Issuer's 2025 Annual Meeting of Shareholders.”
Item 4 in the Schedule 13D/A filed Aug 27, 2026; this amendment did not restate Item 4, so the text is from the filing of Mar 25, 2025.
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Innoviva, Inc.Board seats | Stake reported below 5% | Mar 17, 2025 | Mar 13, 2017 | Proxy contest filed | latest (25) | — |
| Alkermes plc.Board seats | Stake reported below 5% | Aug 24, 2023 | May 10, 2021 | Proxy contest filed | latest (15) | — |
| Amarin Corporation PLC/UKBoard seats | Meeting held; result not captured | Feb 28, 2023 | Jan 24, 2022 | Proxy contest filed | latest (22) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| Sarissa Capital Management LP | — | Schedule 13D/A, filed Jun 12, 2023stake not read from this filing’s format: see the filing | Not in the 13F for the quarter ended Dec 31, 2023 | Feb 14, 2024 |
| Alkermes plc. | 5.0% | Schedule 13D/A, filed Aug 24, 2023 | Reported below 5% in a 13D/A | Aug 24, 2023 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Innoviva, Inc. | Stake reported below 5% | filing | Mar 17, 2025 | Mar 13, 2017 |
| Alkermes plc. | Stake reported below 5% | filing | Aug 24, 2023 | May 10, 2021 |
| Amarin Corporation PLC/UK | No outcome in the filings read | — | Feb 28, 2023 | Jan 24, 2022 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 1 of 4 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
| Company | First 13D | To latest close | SPY same dates | 6 months after | 12 months after |
|---|---|---|---|---|---|
| Ironwood Pharmaceuticals Inc IRWD | Mar 19, 2026 | +45.8%Mar 19, 2026 – Nov 19, 2026 | +8.5% | +35.0%SPY +15.4% | not yet / no price |
Prices: daily closes (Nasdaq), as stored by the site.
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Sarissa Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| Barclays PLC | Schedule 13G | Nov 12, 2025 | 1.9% |
| Bank of America Corp /De/ | Schedule 13G | Nov 14, 2025 | 7.4% |
| Armistice Capital, LLC | Schedule 13G | Feb 17, 2026 | 9.8% |
| Renaissance Technologies LLC | Schedule 13G | May 14, 2026 | 4.9% |
| BlackRock, Inc. | Schedule 13G | Jul 28, 2026 | 8.1% |
| State Street Corporation | Schedule 13G | Aug 7, 2026 | 5.4% |